152 GSK Annual Report 2018 Notes to the financial statements continued 3.
Key accounting judgements and estimates continued Contingent consideration and put option liabilities Pensions and other post-employment benefits The 2018 income statement charge for contingent consideration Judgement and put option liabilities was 1,851 million 2017 2,134 million.
Where a surplus on a defined benefit scheme arises, or there is potential for a surplus to arise from committed future contributions, At 31 December 2018, the liability for contingent consideration the rights of the Trustees to prevent the Group obtaining a refund of amounted to 6,286 million 2017 6,172 million.
Of this amount, that surplus in the future are considered in determining whether it is 5,937 million 2017 5,542 million related to the acquisition necessary to restrict the amount of the surplus that is recognised.
of the former Shionogi-ViiV Healthcare joint venture in 2012 and Four UK schemes are in surplus, with a combined surplus of 711 296 million 2017 584 million related to the acquisition of the million at 31 December 2018 2017 470 million.
GSK has made Vaccines business from Novartis in 2015. the judgement that these amounts meet the requirements of Estimates recoverability.
Any contingent consideration included in the consideration payable Estimates for a business combination is recorded at fair value at the date of The costs of providing pensions and other post-employment benefits acquisition.
These fair values are generally based on risk-adjusted are assessed on the basis of assumptions selected by management.
future cash flows discounted using appropriate post-tax discount These assumptions include future earnings and pension increases, rates.
The fair values are reviewed on a regular basis, at least discount rates, expected long-term rates of return on assets and annually, and any changes are reflected in the income statement.
mortality rates, and are disclosed in Note 28, Pensions and other See Note 39, Contingent consideration liabilities.
In June 2018, GSK acquired Novartis shareholding in the Consumer Discount rates are derived from AA rated corporate bond yields Healthcare Joint Venture for $13 billion.
This resulted in a net charge except in countries where there is no deep market in corporate in the period of 658 million to remeasure the Consumer Healthcare bonds where government bond yields are used.
A sensitivity analysis Joint Venture put option to the agreed valuation.
is provided in Note 28, Pensions and other post-employment Pfizer may request an IPO of ViiV Healthcare at any time and if either benefits, but a 0.25% reduction in the discount rate would lead to an GSK does not consent to such IPO or an offering is not completed increase in the net pension deficit of approximately 707 million and within nine months, Pfizer could require GSK to acquire its an increase in the annual pension cost of approximately 28 million.
The liability for the Pfizer put option, which is derived The selection of different assumptions could affect the future results from an internal valuation of the ViiV Healthcare business, utilising of the Group.
both discounted forecast future cash flow and multiples-based methodologies amounted to 1,240 million at 31 December 2018 2017 1,304 million.
Sensitivity analysis is given in Note 27, Trade and other payables.
New accounting requirements The following new and amended accounting standards have been GSK will implement IFRS 16 applying the modified retrospective issued by the IASB and are likely to affect future Annual Reports.
For larger leases, the right of use asset at 1 January 2019 will be calculated based on the original lease inception date and for IFRS 16 Leases was issued in January 2016 and will be smaller leases the right of use asset will be set equal to the lease implemented by the Group from 1 January 2019.
The Standard will liability, adjusted for any prepaid or accrued lease payments, onerous replace IAS 17 Leases and will require lease liabilities and right of lease provisions and business combination fair value adjustments.
use assets to be recognised on the balance sheet for almost all On the transition date of 1 January 2019, the Group expects to leases.
This is expected to result in a significant increase in both recognise right of use assets of 1.1 billion and a lease liability of assets and liabilities recognised.
The costs of operating leases 1.3 billion, including existing finance leases.
The implementation currently included within operating costs will be split and the is expected to reduce net assets and total equity by 0.1 billion.
financing element of the charge will be reported within finance expense.
The overall impact on earnings is not expected to be material.
Finance lease obligations at 31 December 2018 are set out in Note 31, Net debt and the undiscounted commitments under non-cancellable operating leases are set out in Note 41, Commitments.
